2024

1. A Bioreactor for Celullarised Membrane Culture and Delivery under Sterile Conditions

   Bioengineering, Vol. 11, Núm. 8

2. An automated network-based tool to search for metabolic vulnerabilities in cancer

   Nature Communications , Vol. 15, Núm. 1

3. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

   Haematologica

4. CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?

   Hemato, Vol. 5, Núm. 2, pp. 171-179

5. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC

   Bone Marrow Transplantation

6. Concordancia entre las escalas de valoración del riesgo de tromboembolismo venoso en pacientes con patología médica en urgencias

   Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 36, Núm. 5, pp. 342-350

7. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

   The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

8. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

   Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

9. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

   Nature Communications, Vol. 15, Núm. 1

10. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Blood

11. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

12. Immunothrombosis: A key mechanism in the COVID-19 pandemic

    Medicina Clinica

13. Is tranexamic acid appropriate for all patients undergoing high-risk surgery?

    Current Opinion in Critical Care

14. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

    HemaSphere

15. Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142

16. MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers

    Journal for immunotherapy of cancer, Vol. 12, Núm. 9

17. Myelodysplastic neoplasms

    Medicina Clinica, Vol. 162, Núm. 2, pp. 77-82

18. Novel biomarkers and psoriasis associated cardiovascular risk

    Archives of Dermatological Research, Vol. 316, Núm. 5

19. Oxygen control in bioreactor drives high yield production of functional hiPSC-like hepatocytes for advanced liver disease modelling

    Scientific Reports, Vol. 14, Núm. 1

20. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

    Leukemia